Publications by authors named "WEINTRAUB W"
Background: Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition that can lead to atrial fibrillation, heart failure, and sudden cardiac death in many individuals but mild clinical impact in others. The mechanisms underlying this phenotypic heterogeneity are not well defined. The aim of this study was to use plasma proteomic profiling to help illuminate biomarkers that reflect or inform the heterogeneity observed in HCM.
View Article and Find Full Text PDFBackground: Among patients with aortic stenosis, ventricular remodeling by hypertrophy can limit the augmentation of flow with exertion, even after valve intervention. However, the effect of hypertrophy on quality of life (QoL) improvement has not been studied. We aimed to determine the effect of ventricular hypertrophy on QoL outcomes after transcatheter aortic valve replacement (TAVR).
View Article and Find Full Text PDFCardiac physiologic pacing (CPP) after atrioventricular node (AVN) ablation for persistent atrial fibrillation (AF) has improved outcomes in patients with heart failure with reduced and preserved ejection fraction (HFpEF). Emerging evidence suggests patients with HFpEF benefit from higher heart rates, yet the optimal pacing rate after AVN ablation remains unknown. Optimal Pacing Rate for cardiac resynchronization therapy after atrioventricular node ablation in persistent Atrial Fibrillation and heart failure (OPT-RATE AF) is a prospective, randomized crossover study of patients with HFpEF after AVN ablation for persistent AF (NCT06445439).
View Article and Find Full Text PDFObjective: We aimed to investigate sociodemographic factors associated with self-reported COVID-19 infection.
Methods: The study population was a prospective multicenter cohort of adult volunteers recruited from healthcare systems located in the mid-Atlantic and southern United States. Between April 2020 and October 2021, participants completed daily online questionnaires about symptoms, exposures, and risk behaviors related to COVID-19, including self-reports of positive SARS CoV-2 detection tests and COVID-19 vaccination.
Article Synopsis
- Diagnostic errors in hospitals contribute to preventable deaths and increased patient harm, emphasizing a need for better surveillance methods.
- This study investigates the use of machine learning and natural language processing to enhance the detection of diagnostic errors by analyzing electronic health records and case review data from a health system in the mid-Atlantic U.S.
- Results show that out of 1704 patients, 126 experienced diagnostic errors, with significant differences in error rates and patient demographics between men and women, including age and admission types.
Article Synopsis
- The SOLOIST-WHF trial demonstrated the effectiveness of sotagliflozin in patients with diabetes experiencing worsening heart failure, but its cost-effectiveness had not been studied before.
- The study created a Markov model to analyze the long-term cost and health outcomes of sotagliflozin, utilizing data from the trial and other national sources.
- Results showed that while sotagliflozin increased quality-adjusted life-years (QALYs) and lifetime costs compared to placebo, its incremental cost-effectiveness ratio suggests that it is a cost-effective treatment under common willingness-to-pay thresholds.
Article Synopsis
- The study investigates the complex journey of patients with coronary microvascular dysfunction (CMD) from experiencing chest pain to receiving a formal diagnosis.
- Analyzed data from the Coronary Microvascular Disease Registry revealed that patients typically wait around 0.62 years for a CMD diagnosis, undergoing several diagnostic tests and emergency visits during this time.
- Timely diagnosis of CMD may lead to reduced healthcare costs, fewer emergency visits, and better management of symptoms, highlighting the importance of effective coronary functional testing.
Background: Although statins reduce adverse cardiovascular outcomes, less than one-half of eligible patients receive treatment. A nonprescription statin has the potential to improve access to statins.
Objectives: This study sought to assess concordance between clinician and consumer assessment of eligibility for nonprescription statin treatment using a technology assisted self-selection Web application (Web App) and evaluate effect on low-density lipoprotein cholesterol (LDL-C) levels.
Article Synopsis
- Many people with serious heart problems are using a treatment called CIIS to feel better, even though it doesn’t make them live longer.
- A study asked patients about their thoughts on CIIS, and most believed it would help them feel better and live longer, but only a few thought it would cure their heart issues.
- Overall, most patients felt their quality of life improved with CIIS, but more research is needed to help patients understand what this treatment really does.
Background: Cardiovascular disease (CVD) is among the costliest conditions in the United States, and cost-effectiveness analyses can be used to assess economic impact and prioritize CVD treatments. We aimed to develop standardized, nationally representative CVD events and selected possible CVD treatment-related complication hospitalization costs for use in cost-effectiveness analyses.
Methods: Nationally representative costs were derived using publicly available inpatient hospital discharge data from the 2012-2018 National Inpatient Sample.
Blood pressure (BP) is routinely invasively monitored by an arterial catheter in the intensive care unit (ICU). However, the available data comparing the accuracy of noninvasive methods to arterial catheters for measuring BP in the ICU are limited by small numbers and diverse methodologies. To determine agreement between invasive arterial blood pressure monitoring (IABP) and noninvasive blood pressure (NIBP) in critically ill patients.
View Article and Find Full Text PDFArticle Synopsis
- * The strategies simulated include usual care, intensive care targeting lower blood pressure, and team-based care, indicating varying levels of effectiveness in reducing CVD events.
- * While intensive care could prevent up to 138,100 cardiovascular events annually, it is also associated with a significant increase in serious treatment-related adverse events, raising concerns about safety.
Article Synopsis
- The REDUCE-IT USA trial found that icosapent ethyl (IPE) significantly reduced cardiovascular events by 31% and 36% over approximately 4.9 years.
- An analysis of the cost-effectiveness of IPE compared to standard care (SC) showed that IPE was less expensive and provided better health outcomes, particularly at a daily cost of $4.59.
- Overall, IPE is recommended for U.S. patients similar to those in the trial, as it remains cost-effective even at a higher daily cost of $11.48.
Background: Late gadolinium enhancement (LGE) cardiovascular magnetic resonance (CMR) imaging is the gold standard for non-invasive myocardial tissue characterisation. However, accurate segmentation of the left ventricular (LV) myocardium remains a challenge due to limited training data and lack of quality control. This study addresses these issues by leveraging generative adversarial networks (GAN)-generated virtual native enhancement (VNE) images to expand the training set and incorporating an automated quality control-driven (QCD) framework to improve segmentation reliability.
View Article and Find Full Text PDFCompare heart failure (HF) costs of Furoscix use at home compared with inpatient intravenous (IV) diuresis. Prospective, case control study of chronic HF patients presenting to emergency department (ED) with worsening congestion discharged to receive Furoscix 80 mg/10 ml 5-h subcutaneous infusion for ≤7 days. 30-day HF-related costs in Furoscix group derived from commercial claims database compared with matched historical patients hospitalized for <72 h.
View Article and Find Full Text PDFContext: Heart disease (HD) is a primary cause of mortality and morbidity in the United States. While there is a growing body of evidence demonstrating the contribution of social determinants of health (SDoH) to HD outcomes, the impact of combined or individual SDoH on health-related quality of life (HRQoL) in patients with HD is not well understood.
Objectives: To analyze the National Health and Aging Trends Study (NHATS) to explore the relationship of SDoH with HRQoL, advance care planning, and treatment preferences in Medicare beneficiaries with HD.